Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 3 of 1112345...10...Last »

Nearly 500 Amgen Staffers to be Reassigned, Relocated or Laid Off in Restructuring

Up to 500 Amgen employees based at the company’s Thousand Oaks facilities will be relocated to a new site in Tampa, Fla. and other sites, or be terminated, over the next 18 months as part of a new restructuring plan.

Read More »

Johnson & Johnson’s $100,000 Anti-Burnout Program for Top Execs

Johnson & Johnson’s Human Performance Institute has developed a Premier Executive Leadership program to help executives avoid burnout.

Read More »

Chinese drug approval for AstraZeneca’s Tagrisso

AstraZeneca has won approval for its lung cancer pill Tagrisso in China, a key market for the potential blockbuster medicine.

Read More »

Trump tastes failure as U.S. House healthcare bill collapses

President Donald Trump suffered a stunning political setback in a Congress controlled by his own party when Republican leaders pulled legislation to overhaul the U.S. healthcare system, a major 2016 election campaign promise of the president and his allies.

Read More »

House clears way for debate on Trump-backed healthcare bill

The Republican-controlled U.S. House of Representatives cleared the way for a contentious debate on legislation to repeal Obamacare and replace it with a more limited federal healthcare insurance program.

Read More »

Pfizer Receives Positive CHMP Opinion for Trumenba for Prevention of Meningococcal Group B Disease

Pfizer Inc. today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that Trumenba (Meningococcal Group B Vaccine) be granted marketing authorization in the European Union for active immunization of individuals 10 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB).

Read More »

EMA panel backs Novo Nordisk’s hemophilia B drug

A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk’s hemophilia B drug.

Read More »

Why pressure is mounting for life sciences to take digital transformation seriously

Habit and red tape are not sufficient excuses for life sciences organizations to keep doing things the way they always have.

Read More »

Judge dismisses two Express Scripts claims

A federal judge dismissed two of the six counterclaims that Express Scripts raised in health insurer’s Anthem’s $15 billion lawsuit claiming it charged too much for drugs.

Read More »

Drugmaker Lilly to invest $850 million in U.S. operations in 2017

Eli Lilly and Co. said it would invest $850 million in its U.S. operations during 2017, and the drugmaker signaled it would be willing to spend more if the Trump administration were to overhaul tax laws.

Read More »

FDA Approves Symproic for OIC

The U.S. FDA approved Symproic (naldemedine) 0.2 mg tablets C-II for treating opioid-induced constipation in adult patients with chronic non-cancer pain.

Read More »

Get The Study Papers Accomplished Swiftly Without the need of Wasting Time

Get The Study Papers Accomplished Swiftly Without the need of Wasting Time The principle intent behind a study papers would be to instruct pupils more about their topic or task than what the manual gives.

Read More »

FDA Grants Approval for Bavencio

The U.S. FDA approved Bavencio (avelumab) Injection 20 mg/mL for ttreating adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma.

Read More »

HYC Health Adds Three to Team

Fast-growing healthcare and pharma agency HYC Health has hired Chris DeProfio as VP, account director, and Jim Kopeny and George Starr as associate creative directors.

Read More »

Discovery of Novel Screening Test That Can Identify Patients at Risk of Life-Threatening Side Effect with Certain Anticonvulsant Medications

A new genetic test has been discovered that allows for fast and accurate identification of individuals who carry HLA-B*15:02 and who are therefore at risk for a rare yet potentially deadly side effect of certain medications used to treat seizures and bipolar disorder.

Read More »

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

Three of Europe’s top drugmakers face critical verdicts from U.S. regulators, with Sanofi and Roche likely to win approvals for two new products while GlaxoSmithKline braces for a potential generic rival.

Read More »

Ultragenyx Seizure Drug Flunks Phase II Test

Shares of Ultragenyx Pharmaceuticals were down after the company announced its Phase II drug UX007 to treat seizures failed to meet trial goals.

Read More »

Teva Backpedals on 6,000 Job Cuts, Says Figure is Too High

Israel-based Teva Pharmaceutical Industries corrected a news report saying the company was cutting 2,000 to 6,000 jobs. The company did not specify the actual number, although it did say 6,000 was too high.

Read More »

Scientists use graphene to power ‘electronic skin’ that can feel

Scientists have found a way to power an experimental kind of electronic skin using solar energy in a further step towards the development of prosthetic limbs or robots with a sense of touch.

Read More »

GSK and Regeneron to mine gene data

GlaxoSmithKline and Regeneron Pharmaceuticals are embarking on a joint project with UK Biobank to hunt for new clues linking genes and disease.

Read More »

Page 3 of 1112345...10...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation